Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
BPMCBlueprint Medicines(BPMC) Prnewswire·2024-05-02 19:00

-- Achieved 92.5millioninAYVAKITnetproductrevenuesinthefirstquarter2024−−−−Raisingguidanceto92.5 million in AYVAKIT net product revenues in the first quarter 2024 -- -- Raising guidance to 390 million to $410 million in full year AYVAKIT net product revenues -- -- Strengthening presence in allergy and inflammation with the IND for wild-type KIT inhibitor BLU-808 on track for filing in Q2 -- CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2024 ...